Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): A double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

J Gallant, A Lazzarin, A Mills, C Orkin, D Podzamczer, P Tebas, PM Girard, I Brar, ES Daar, D Wohl, J Rockstroh, X Wei, J Custodio, K White, H Martin, A Cheng, E Quirk

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): A double-blind, multicentre, phase 3, randomised controlled non-inferiority trial'. Together they form a unique fingerprint.

Medicine & Life Sciences